Phase III confirmatory study of KP-001 in patients with venous malformation, lymphatic malformation and Klippel-Trenaunay Syndrome

Kaken Pharmaceutical Co. Ltd.0 个研究点目标入组 32 人开始时间: 待定最近更新: 2024年7月9日

试验速览

暂无简介。

•Patient is at least 2 years of age at time of consent
•Diagnosed as ISSVA classification of Common VM, Common (cystic) LM (including combined type mainly consisting of VM or LM), or Klippel-Trenaunay Syndrome
•Diagnosed as pain, bleeding, disfigurement, inflammation such as cellulitis, etc., and judged to be symptomatic
•Diagnosed as refractory because resection is not curative, resection is difficult, or for other reasons
•Patients with at least one target lesion that can be volumetrically measured by MRI at screening

•Patients with the following diseases: simple capillary malformation, lymphangiomatosis, lymphangioleiomyomatosis in Gorham-Stout disease, lymphangiectasia, familial VM cutaneo-mucosal, blue rubber bleb nevus syndrome, M-CM/MCAP, CLOVE(S) syndrome, CLAPO syndrome, proteus syndrome, Parkes Weber syndrome, Sturge-Weber syndrome, maffucci syndrome, Rendu-Osler-Weber syndrome, Cowden's disease, Adams-Oliver syndrome
•Patients with diabetes mellitus (type I or II) or diseases with abnormal glucose metabolism (glycogen storage disease, hypergalactosemia, primary lactose intolerance, etc.)
•Diagnosed as having hepatic or renal impairment
•Patients with ischemic heart disease, arrhythmia, or heart failure (NYHA III or IV degree) diagnosed as inadequately controlled
•Diagnosed as having a gastrointestinal disorder that affects drug absorption
•Patients who are unable to take the drug orally
•Patients with orthodontic appliances, cochlear implants, etc. which may affect MRI imaging
•Patients with target lesion infection requiring treatment within 28 days prior to screening
•Patients who have undergone invasive treatment, including sclerotherapy or laser therapy, for the target lesion within 84 days prior to screening
•Patients who have used other PI3Ka inhibitors or Sirolimus within 84 days prior to screening

Target lesion response based on MRI at the last evaluation after 24 weeks of treatment

未报告次要终点

发起方

Kaken Pharmaceutical Co. Ltd.